Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBAI20 (CyTuVax, c52e8f)
- Development stage
- Unknown
- Lead developer
- CyTuVax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
HBAI20 is an investigational prophylactic vaccine developed by CyTuVax BV for the prevention of hepatitis B virus (HBV) infection, specifically targeting individuals who do not respond adequately to standard hepatitis B vaccines. The vaccine is a combination of the licensed HBVaxPro-10 µg (containing recombinant hepatitis B surface antigen, HBsAg) and a novel adjuvant called AI20. AI20 consists of recombinant human interleukin-2 (IL-2) adsorbed onto aluminum hydroxide (alum), which creates a depot at the injection site. This depot allows for the slow, sustained release of IL-2, which acts as an immunostimulant to enhance the T-cell and B-cell responses to the HBsAg antigen. In Phase 2 clinical trials, HBAI20 demonstrated significantly higher seroprotection rates in previous non-responders compared to standard vaccination.
- Other names
- HBAI20-adjuvanted hepatitis B vaccineHBAI-20-adjuvanted hepatitis B vaccineHBAI 20-adjuvanted hepatitis B vaccineCyTuVax hepatitis B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)IL-2R (Interleukin-2/interleukin-15 receptor complex)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on HBAI20 (CyTuVax, c52e8f).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBAI20 (CyTuVax, c52e8f).